Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Religa, D. Articles by Haroutunian, V. Search for Related Content PubMed Citation Articles by Religa, D. Articles by Haroutunian, V. Neurodegeneration Geriatric Psychiatry Alzheimer's Disease Schizophrenia Spectrum Disorders Cognition

Amyloid ß Pathology in Alzheimer’s Disease and Schizophrenia

OBJECTIVE: Severe cognitive impairment is common in elderly patients with schizophrenia. Alzheimer’s disease is the main cause of dementia among the elderly. Biochemical and genetic studies suggest that amyloid ß-peptide is central in Alzheimer’s disease. The authors examined the possible involvement of amyloid ß-peptide in cognitive impairment in schizophrenia. METHOD: Specific antibodies against two major forms of amyloid ß-peptide, Aßx-40 and Aßx-42, were used in sandwich enzyme-linked immunosorbent assays to determine the levels of amyloid ß-peptide in postmortem brain samples from Alzheimer’s disease patients (N=10), normal elderly comparison subjects (N=11), and schizophrenia patients with (N=7) or without (N=26) Alzheimer’s disease. RESULTS: The levels of amyloid ß-peptide were highest in the Alzheimer’s disease patients, followed by the patients with schizophrenia and comparison subjects. The mean Aßx-42 level in the schizophrenia patients without Alzheimer’s disease was similar to that in the comparison subjects, but the level in the schizophrenia patients with Alzheimer’s disease was significantly higher than in those without Alzheimer’s disease or the comparison subjects. The Aßx-42 level in the schizophrenia patients with Alzheimer’s disease was significantly lower than the level in the Alzheimer’s disease cohort. CONCLUSIONS: In contrast to elderly schizophrenia patients with Alzheimer’s disease pathology, those without Alzheimer’s disease had amyloid ß-peptide levels that were not significantly different from those of normal subjects; hence amyloid ß-peptide does not account for the cognitive deficits in this group. These results suggest that the causes of cognitive impairment in "pure" schizophrenia are different from those in Alzheimer’s disease.

This article has been cited by other articles:

				D. Religa, D. Strozyk, R. A. Cherny, I. Volitakis, V. Haroutunian, B. Winblad, J. Naslund, and A. I. Bush Elevated cortical zinc in Alzheimer disease. Neurology, July 11, 2006; 67(1): 69 - 75. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us